Anti-CTLA-4 or anti-PD-L1/PD-1 fully humanized antibodies, which target immune checkpoint molecules expressed by cTreg cells upon activation, have shown promising results in clinical studies treating various cancer types (31, 33). The gene discussed is CTLA4; the disease is cancer.